Published in J Clin Invest on July 01, 1983
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci. Infect Immun (1987) 1.39
Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J Exp Med (1989) 1.33
Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1992) 1.27
Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun (1989) 1.13
Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Infect Immun (2005) 1.00
Interaction of soluble fibronectin with group B streptococci. Infect Immun (1987) 0.93
A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine (2013) 0.84
Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc Natl Acad Sci U S A (2008) 0.84
Opsonic effect of jacalin and human immunoglobulin A on type II group B streptococci. Infect Immun (1990) 0.82
[A micro-method of immuno-electrophoresis]. Int Arch Allergy Appl Immunol (1955) 52.23
Diffusion-in-gel methods for immunological analysis. Prog Allergy (1958) 27.50
Variation in the group-specific carbohydrate of group A streptococci. I. Immunochemical studies on the carbohydrates of variant strains. J Exp Med (1955) 10.31
Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med (1975) 7.02
Distribution by serological type of group B streptococci isolated from a variety of clinical material over a five-year period (with special reference to neonatal sepsis and meningitis). Infect Immun (1973) 7.01
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) (1966) 4.55
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
ANTIGENIC RELATIONSHIPS BETWEEN GROUPS B AND G STREPTOCOCCI. J Exp Med (1964) 3.70
Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest (1976) 3.04
Type-specific polysaccharide antigens of group B streptococci. II. The chemical basis for serological specificity of the type II HCl antigen. J Exp Med (1967) 2.92
Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem (1975) 2.51
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand (1977) 2.11
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Soluble group- and type-specific antigens from type III group B Streptococcus. Infect Immun (1980) 1.98
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem (1980) 1.83
Group B streptococcal infections. Adv Intern Med (1980) 1.72
Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry (1983) 1.54
Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus. J Biol Chem (1983) 1.46
Multiple polysaccharide antigens of group B streptococcus, type Ia: emphasis on a sialic acid type-specific polysaccharide. J Immunol (1977) 1.45
Immunochemical characterization of native polysaccharides from group B streptococcus: the relationship of the type III and group B determinants. J Immunol (1978) 1.18
Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci. J Clin Microbiol (1978) 1.18
Structure and serology of the native polysaccharide antigen of type Ia group B streptococcus. Proc Natl Acad Sci U S A (1980) 1.12
Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med (1980) 1.07
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis (1972) 4.54
Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol (1973) 4.49
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Selective broth medium for isolation of group B streptococci. Appl Microbiol (1973) 4.42
Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A (1987) 3.99
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis (1983) 3.23
The polysaccharide capsule of Bacteroides fragilis subspecies fragilis: immunochemical and morphologic definition. J Infect Dis (1976) 3.20
Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med (1988) 3.14
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol (1981) 3.04
Active oxygen in plant pathogenesis. Annu Rev Phytopathol (1995) 3.02
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest (1990) 2.96
Bacteroides fragilis subspecies in clinical isolates. Ann Intern Med (1977) 2.95
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Molecular cloning of a Pseudomonas syringae pv. syringae gene cluster that enables Pseudomonas fluorescens to elicit the hypersensitive response in tobacco plants. J Bacteriol (1988) 2.84
Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature (2001) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A (1992) 2.65
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem (1975) 2.51
Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis (1999) 2.50
Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis. J Infect Dis (1973) 2.47
Involvement of plasma membrane calcium influx in bacterial induction of the k/h and hypersensitive responses in tobacco. Plant Physiol (1990) 2.46
Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection. J Clin Invest (1977) 2.46
Neonatal sepsis caused by a new group B streptococcal serotype. J Pediatr (1993) 2.45
Chemical and biological characterization of the lipopolysaccharide of Bacteroides fragilis subspecies fragilis. J Infect Dis (1976) 2.45
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis. J Infect Dis (1975) 2.39
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J Biol Chem (1987) 2.35
Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A (1996) 2.34
Functional analysis in type Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production by diverse species of streptococci. J Biol Chem (2001) 2.30
In whose best interest? Breaching the academic-industrial wall. N Engl J Med (2000) 2.28
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry (1981) 2.17
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A (1989) 2.13
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun (1991) 2.06
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 2.02
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem (1992) 2.00
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother (1998) 2.00
Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry (1992) 1.98
Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun (1991) 1.97
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. Infect Immun (1991) 1.95
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
The changing spectrum of group B streptococcal disease. N Engl J Med (1993) 1.94
Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest (1995) 1.91
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. J Clin Microbiol (1989) 1.87
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83
Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem (1980) 1.83
Neonatal mouse model of group B streptococcal infection. J Infect Dis (1992) 1.82
Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1. Biochemistry (1980) 1.80
Mouse protection test for group B Streptococcus type III. J Infect Dis (1979) 1.80
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis (2000) 1.79
Persistent bacteremia due to coagulase-negative staphylococci in low birth weight neonates. Pediatrics (1989) 1.78
Vaginal colonization with group B streptococcus: a study in college women. J Infect Dis (1977) 1.76
The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res (1983) 1.75
Group B streptococcal vaccines. Rev Infect Dis (1985) 1.74
Isolation and identification of encapsulated strains of Bacteroides fragilis. J Infect Dis (1977) 1.74
Group B streptococcal infections. Adv Intern Med (1980) 1.72
Antimicrobial susceptibility of group B streptococci isolated from a variety of clinical sources. Antimicrob Agents Chemother (1976) 1.72
Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis (1979) 1.71
Group B streptococcal cellulitis-adenitis in infants. Am J Dis Child (1982) 1.71